在B细胞急性淋巴细胞白血病的IKZF1变化和治疗向
Jonathan Paolino1,2, Harrison K Tsai3, Marian H Harris3
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Biomedicines
|January 23, 2024
概括
在IKZF1基因中删除破坏了B细胞急性淋巴细胞白血病 (B-ALL) 的IKAROS功能,促进了侵袭性癌症的生长. 早期识别这些IKZF1删除可以指导加强治疗策略,以获得更好的患者结果.
科学领域:
- 遗传学 遗传学 是一个
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 该IKZF1基因编码IKAROS转录因子,对于正常的淋巴细胞发育至关重要.
- 伊卡洛斯在建立血统受限成熟淋巴细胞方面发挥着至关重要的作用.
- IKAROS功能的失调与各种血液性恶性瘤有关.
研究的目的:
- 研究IKZF1缺失在B细胞急性淋巴细胞白血病 (B-ALL) 的功能后果.
- 确定IKZF1删除和B-ALL中治疗耐药性之间的关联.
- 评估IKZF1删除早期检测在B-ALL管理中的潜在临床实用性.
主要方法:
- 在B-ALL患者样本中分析IKZF1基因状态.
- 功能性测试以评估IKAROS蛋白活性和下游效应.
- 相关性研究将IKZF1删除状态与临床结果和治疗反应联系起来.
主要成果:
- 在B-ALL中的IKZF1缺失导致正常IKAROS功能丧失.
- 失去了IKAROS的功能赋予了白血病干细胞的特性,包括自我更新和不受控制的增殖.
- IKZF1缺失与B-ALL患者的治疗耐药性和更差的预后有显著的关联.
结论:
- IKZF1的缺失是B-ALL中侵袭性疾病和治疗失败的关键驱动因素.
- 早期发现IKZF1缺失对于识别高风险患者至关重要.
- 根据IKZF1删除状态的目标治疗策略可以改善B-ALL.的结果.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:26NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K